{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:09:34Z","timestamp":1790291374300,"version":"4.1.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Amikacin, kanamycin, and capreomycin are among the most important second-line drugs for multidrug-resistant tuberculosis. Although amikacin and kanamycin are administered at the same dose and show the same pharmacokinetics, they have different WHO breakpoints, suggesting that the two drugs have different MICs. The aim of this study was to investigate possible differences in MICs between the aminoglycosides and capreomycin. Using the direct concentration method, a range of concentrations of amikacin, kanamycin, and capreomycin (0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, and 64.0 mg\/liter) were tested against 57 clinical\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            strains. The 7H10 agar plates were examined for mycobacterial growth after 14 days. At 2 mg\/liter, 48 strains (84%) were inhibited by amikacin and only 5 strains (9%) were inhibited by kanamycin (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05, Wilcoxon signed-rank test). The median MICs of amikacin, kanamycin, and capreomycin were 2, 4, and 8 mg\/liter, respectively. No difference in amikacin, kanamycin, and capreomycin MIC distributions was observed between multidrug-resistant strains and fully susceptible strains. The results indicate that amikacin is more active than kanamycin and capreomycin against\n            <jats:named-content content-type=\"genus-species\">M. tuberculosis<\/jats:named-content>\n            with the absolute concentration method. Determination of the impact of this difference on clinical outcomes in daily practice requires a prospective study, including pharmacokinetic and pharmacodynamic evaluations.\n          <\/jats:p>","DOI":"10.1128\/aac.01724-17","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T20:32:19Z","timestamp":1515184339000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["<i>In Vitro<\/i>\n            Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin"],"prefix":"10.1128","volume":"62","author":[{"given":"J. A.","family":"Dijkstra","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van der Laan","sequence":"additional","affiliation":[{"name":"National Mycobacteria Reference Laboratory, National Institute of Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. W.","family":"Akkerman","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Bolhuis","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. C. M.","family":"de Lange","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"},{"name":"University of Groningen, Department of Pharmacy, Unit of Pharmacotherapy, Epidemiology, and Economy, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Soolingen","sequence":"additional","affiliation":[{"name":"National Mycobacteria Reference Laboratory, National Institute of Public Health and the Environment, Bilthoven, The Netherlands"},{"name":"Radboud University Medical Center, Department of Pulmonary Diseases, Nijmegen, The Netherlands"},{"name":"Radboud University Medical Center, Department of Medical Microbiology, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"WHO treatment guidelines for drug-resistant tuberculosis, 2016 update","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. World Health Organization, Geneva, Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/250125\/1\/9789241549639-eng.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.10.3179-3186.1999"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.3.688-692.2006"},{"key":"e_1_3_2_5_2","volume-title":"Updated interim critical concentrations for first-line and second-line DST (as of May 2012)","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Updated interim critical concentrations for first-line and second-line DST (as of May 2012). World Health Organization, Geneva, Switzerland. http:\/\/www.stoptb.org\/wg\/gli\/assets\/documents\/Updated%20critical%20concentration%20table_1st%20and%202nd%20line%20drugs.pdf."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00240-10"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002849900095"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/321854"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00961-16"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/420742"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1162785"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.191"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03025-15"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.27"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-3879(82)80031-7"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03008-15"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr109"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2971-2973.2003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907925106"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02059-14"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01400-16"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-369"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-15"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00244-07"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.11.2398"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.06.008"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01724-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01724-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:04:56Z","timestamp":1645477496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01724-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1128\/AAC.01724-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01724-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"2017-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01724-17"}}